Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12490974rdf:typepubmed:Citationlld:pubmed
pubmed-article:12490974lifeskim:mentionsumls-concept:C0027651lld:lifeskim
pubmed-article:12490974lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:12490974lifeskim:mentionsumls-concept:C0699791lld:lifeskim
pubmed-article:12490974lifeskim:mentionsumls-concept:C0450429lld:lifeskim
pubmed-article:12490974lifeskim:mentionsumls-concept:C0038952lld:lifeskim
pubmed-article:12490974lifeskim:mentionsumls-concept:C1710625lld:lifeskim
pubmed-article:12490974lifeskim:mentionsumls-concept:C0332281lld:lifeskim
pubmed-article:12490974lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:12490974lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:12490974lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:12490974pubmed:issue4lld:pubmed
pubmed-article:12490974pubmed:dateCreated2002-12-19lld:pubmed
pubmed-article:12490974pubmed:abstractTextThe HER-2/neu gene or c-erb B-2, localized on chromosome 17q, belongs to a family of tyrosine kinase receptors and shares extensive homology with the epidermal growth factor receptor. c-erb B-2 gene amplification and protein overexpression have been reported in several human cancers. The prognostic value of this genetic alteration in gastric carcinoma is far from being established. In the present study, formalin-fixed, paraffin-embedded gastric carcinoma tissues from 157 patients were evaluated for c-erb B-2 overexpression, by immunohistochemistry using a polyclonal antibody. c-erb B-2 expression was evaluated according to clinical and pathological parameters, and to the survival of the patients. Our results show that: (1). c-erb B-2 was overexpressed in 15.3% of gastric carcinoma cases; (2). c-erb B-2 overexpression was significantly more frequent in cardia (23.8%) and fundus/body (25.0%) carcinomas than in antrum (7.2%) carcinomas; (3). c-erb B-2 overexpression was significantly associated with venous invasion; (4). c-erb B-2 is a prognostic factor for gastric carcinoma.lld:pubmed
pubmed-article:12490974pubmed:languageenglld:pubmed
pubmed-article:12490974pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12490974pubmed:citationSubsetIMlld:pubmed
pubmed-article:12490974pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12490974pubmed:statusMEDLINElld:pubmed
pubmed-article:12490974pubmed:monthOctlld:pubmed
pubmed-article:12490974pubmed:issn1066-8969lld:pubmed
pubmed-article:12490974pubmed:authorpubmed-author:Pinto-de-Sous...lld:pubmed
pubmed-article:12490974pubmed:authorpubmed-author:DavidLeonorLlld:pubmed
pubmed-article:12490974pubmed:authorpubmed-author:PimentaAmadeu...lld:pubmed
pubmed-article:12490974pubmed:authorpubmed-author:AlmeidaRaquel...lld:pubmed
pubmed-article:12490974pubmed:authorpubmed-author:LeitãoDinaDlld:pubmed
pubmed-article:12490974pubmed:authorpubmed-author:PretoJohn RJRlld:pubmed
pubmed-article:12490974pubmed:authorpubmed-author:SeixasMárioMlld:pubmed
pubmed-article:12490974pubmed:issnTypePrintlld:pubmed
pubmed-article:12490974pubmed:volume10lld:pubmed
pubmed-article:12490974pubmed:ownerNLMlld:pubmed
pubmed-article:12490974pubmed:authorsCompleteYlld:pubmed
pubmed-article:12490974pubmed:pagination247-56lld:pubmed
pubmed-article:12490974pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:12490974pubmed:meshHeadingpubmed-meshheading:12490974...lld:pubmed
pubmed-article:12490974pubmed:meshHeadingpubmed-meshheading:12490974...lld:pubmed
pubmed-article:12490974pubmed:meshHeadingpubmed-meshheading:12490974...lld:pubmed
pubmed-article:12490974pubmed:meshHeadingpubmed-meshheading:12490974...lld:pubmed
pubmed-article:12490974pubmed:meshHeadingpubmed-meshheading:12490974...lld:pubmed
pubmed-article:12490974pubmed:meshHeadingpubmed-meshheading:12490974...lld:pubmed
pubmed-article:12490974pubmed:meshHeadingpubmed-meshheading:12490974...lld:pubmed
pubmed-article:12490974pubmed:meshHeadingpubmed-meshheading:12490974...lld:pubmed
pubmed-article:12490974pubmed:meshHeadingpubmed-meshheading:12490974...lld:pubmed
pubmed-article:12490974pubmed:meshHeadingpubmed-meshheading:12490974...lld:pubmed
pubmed-article:12490974pubmed:meshHeadingpubmed-meshheading:12490974...lld:pubmed
pubmed-article:12490974pubmed:meshHeadingpubmed-meshheading:12490974...lld:pubmed
pubmed-article:12490974pubmed:meshHeadingpubmed-meshheading:12490974...lld:pubmed
pubmed-article:12490974pubmed:meshHeadingpubmed-meshheading:12490974...lld:pubmed
pubmed-article:12490974pubmed:meshHeadingpubmed-meshheading:12490974...lld:pubmed
pubmed-article:12490974pubmed:year2002lld:pubmed
pubmed-article:12490974pubmed:articleTitlec-erb B-2 expression is associated with tumor location and venous invasion and influences survival of patients with gastric carcinoma.lld:pubmed
pubmed-article:12490974pubmed:affiliationSurgery 4, Hospital S João, Porto, Portugal.lld:pubmed
pubmed-article:12490974pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12490974pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed